Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill

Apr 30 2017

• By Michael Cipriano

Capitol House

Related Content

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says

Mar 03 2016

REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing

Mar 03 2017

Bill To Speed ANDA Approvals Gets Cool Reception From Industry, US FDA

Mar 03 2017

FDA User Fee Hearing Hijacked By US Health Care Reform Arguments

Mar 22 2017

REMS Abuses: Congressional Panel’s Focus Turns To Federal Trade Commission

Mar 23 2017

REMS “Abuses” Concern FDA, But Can Scolding Help Speed Generic Entry?

Mar 04 2015

REMS Abuse Legislation: GPhA and PhRMA Set To Battle Again

Jun 16 2016

Shkreli Fallout Continues: PhRMA Seems To Soften Stance On REMS Legislation

Jun 22 2016

Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review

Feb 03 2017

Related Companies

Bristol Myers Squibb Company

Viatris Inc.

Additional Topics

United States Pricing Debate Generic Drugs Market Access BioPharmaceutical

More from Pricing Debate

More from Market Access

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window